Twist Bioscience Corp

Twist Bioscience maintains a conservative capital structure characterized by zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet reflects total assets of $641.9 million against total liabilities of $168.9 million, yielding total equity of $472.96 million. Liquidity is supported by cash and equivalents of $183.05 million, which provides a buffer against operating cash flow outflows of $47.63 million. The current ratio is not explicitly provided, but the absence of debt and substantial cash reserves indicate low immediate liquidity risk. Capital expenditures of $28.0 million were recorded in the latest period, suggesting ongoing investment in infrastructure despite negative operating cash flow.

Profitability metrics indicate the company is in an investment phase, with a net loss of $77.67 million and operating income of -$136.26 million on revenues of $376.57 million. Return on equity stands at -17.18% and return on assets at -12.66%, reflecting the drag of accumulated losses on the equity base. The valuation snapshot shows a price-to-book ratio of 11.74 and an EV/Revenue multiple of 13.11, indicating that the market prices the company based on future growth expectations rather than current earnings. The negative EV/EBITDA of -59.68 further underscores the current lack of profitability.

Segment and geographic revenue mix data is not present in the provided input, preventing a detailed analysis of revenue concentration or regional exposure. The company’s revenue generation is attributed to its core biotechnology activities, but specific breakdowns by product line or geography are omitted from the available data.

Growth trajectory analysis is limited by the absence of historical period data in the input. Without 5-year annual or 8-quarter quarterly revenue and net income trends, it is not possible to assess the momentum of revenue growth or the trajectory of profitability improvements. The current revenue figure of $376.57 million serves as the sole data point for scale assessment.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company’s share count remains stable with 60.63 million basic and diluted shares outstanding, suggesting no recent significant equity issuances. The primary financial risks appear to be operational, centered on the ability to convert revenue growth into profitability, given the current negative operating income and cash flow.

Recent observations from investor relations data show strong analyst sentiment, with a mean recommendation of 1.50 (where 1 is strong buy) and a mean price target of $94.33. The median price target is $95.00, with a high of $120.00 and a low of $60.00. There are 5 strong-buy and 5 buy ratings, with no hold ratings, indicating uniform bullishness among covering analysts. No specific filing, news, or transcript observations were provided in the input data.

Twist Bioscience Corp (TWST.O) experienced a significant modification in its shareholder registry, flagged as a major severity event. The data indicates a substantial shift in holdings for investor ID 587, with share counts oscillating between 116 and 842 shares as of March 31, 2026. These changes were detected in late June 2026, highlighting a notable adjustment in the position size of this specific holder within the company's top 32 investors. The magnitude of this change is underscored by the corresponding fluctuation in portfolio weight, which moved between approximately 0.000003% and 0.000023%. While the absolute dollar value of the position remained minimal—ranging from $5,512 to $40,012—the relative increase in share count represents a more than seven-fold expansion at its peak. This activity suggests active management or correction of the holding by the investor during the reporting period. Despite this specific holder activity, the broader material landscape for Twist Bioscience remained static. An analysis of 17 key fields revealed no material changes compared to prior assessments, with only four fields excluded due to schema expansion. This indicates that while individual shareholder positions may be adjusting, the fundamental operational or financial metrics tracked in the company's core profile have not undergone significant shifts. The company continues to operate with a lean executive structure, reporting only one officer, and currently lacks coverage from analysts or inclusion in major indices. With 32 top holders identified, the recent activity by investor ID 587 represents a discrete event within a relatively concentrated ownership base. The absence of cross-source signals or saga-related developments further isolates this holder change as a standalone administrative or strategic adjustment rather than part of a larger corporate narrative.

Revenue grew 20.3% year-over-year to $376.6 million in fiscal 2025, demonstrating strong top-line expansion momentum.

Net income improved significantly by 62.8% year-over-year, narrowing the loss to $77.7 million in fiscal 2025.

Free cash flow improved by 55.7% year-over-year to a negative $80.8 million, indicating better cash generation efficiency.

The company maintains a low leverage band with a debt-to-equity ratio of 0.36 and a strong current ratio of 3.64.

Cash conversion metrics rank above the biotechnology cohort median, suggesting efficient capital deployment relative to peers.

The company remains unprofitable with a negative net margin of -19.8%, significantly worse than the biotechnology cohort median.

Revenue $110.7M, +19,3% YoY; Operating income −10,3% YoY.

• ▍Revenue $110.7M, +19,3% YoY
• ▍Operating income −10,3% YoY
• ▍Net income −11,9% YoY
• ▍Free cash flow −37,6% YoY
• ▍Net margin -39.8%

Revenue $103.7M, +16,9% YoY; Operating income +5,0% YoY.

• ▍Revenue $103.7M, +16,9% YoY
• ▍Operating income +5,0% YoY
• ▍Net income +3,4% YoY
• ▍Free cash flow −24,8% YoY
• ▍Net margin -29.4%

Revenue $99.0M, +16,9% YoY; Operating income +16,9% YoY.

• ▍Revenue $99.0M, +16,9% YoY
• ▍Operating income +16,9% YoY
• ▍Net income +21,7% YoY
• ▍Free cash flow −11,7% YoY
• ▍Net margin -27.4%

Revenue $96.1M, +17,9% YoY; Operating income +121,1% YoY.

• ▍Revenue $96.1M, +17,9% YoY
• ▍Operating income +121,1% YoY
• ▍Net income +123,8% YoY
• ▍Free cash flow +122,1% YoY
• ▍Net margin 21.2%

Revenue $92.8M; Operating income -$41.6M.

• ▍Revenue $92.8M
• ▍Operating income -$41.6M
• ▍Net margin -42.4%

Revenue $88.7M; Operating income -$34.6M.

• ▍Revenue $88.7M
• ▍Operating income -$34.6M
• ▍Net margin -35.6%

Revenue $84.7M; Operating income -$36.0M.

• ▍Revenue $84.7M
• ▍Operating income -$36.0M
• ▍Net margin -40.9%

Revenue $81.5M; Operating income -$88.9M.

• ▍Revenue $81.5M
• ▍Operating income -$88.9M
• ▍Net margin -105.0%

Revenue $376.6M, +20,3% YoY; Operating income +60,4% YoY.

• ▍Revenue $376.6M, +20,3% YoY
• ▍Operating income +60,4% YoY
• ▍Net income +62,8% YoY
• ▍Free cash flow +55,7% YoY
• ▍Net margin -20.6%

Revenue $313.0M, +27,7% YoY; Operating income −1,7% YoY.

• ▍Revenue $313.0M, +27,7% YoY
• ▍Operating income −1,7% YoY
• ▍Net income −2,0% YoY
• ▍Free cash flow +7,8% YoY
• ▍Net margin -66.7%

Revenue $245.1M, +20,4% YoY; Operating income +5,7% YoY.

• ▍Revenue $245.1M, +20,4% YoY
• ▍Operating income +5,7% YoY
• ▍Net income +6,1% YoY
• ▍Free cash flow +33,7% YoY
• ▍Net margin -83.5%

Revenue $203.6M, +53,8% YoY; Operating income −50,7% YoY.

• ▍Revenue $203.6M, +53,8% YoY
• ▍Operating income −50,7% YoY
• ▍Net income −43,2% YoY
• ▍Free cash flow −76,7% YoY
• ▍Net margin -107.0%